One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Ascendis Pharma ADR cleared that benchmark Thursday, with a jump from 77 to 81 Thursday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an RS Rating of above 80 in the early stages of their moves.
Ascendis Pharma ADR broke out earlier, but is now trading about 5% below the prior 179.40 entry from a cup with handle. In the case where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new pattern to take shape. Also keep in mind that the most recent consolidation is a later-stage base, and those involve more risk.
Ascendis Pharma ADR reported 0% earnings growth in its most recent report. Revenue rose 6%.
Ascendis Pharma ADR holds the No. 121 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Harmony Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
